限定小陈
Lv11
60 积分
2023-03-05 加入
-
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
2天前
已完结
-
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials
2天前
已完结
-
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
2天前
已完结
-
Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment
3个月前
已完结
-
MET alterations in NSCLC—Current Perspectives and Future Challenges
8个月前
已完结
-
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
8个月前
已完结
-
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer
8个月前
已完结
-
Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer
9个月前
已完结
-
Albumin‐Hitchhiking Drug Delivery to Tumor‐Draining Lymph Nodes Precisely Boosts Tumor‐Specific Immunity through Autophagy Modulation of Immune Cells
10个月前
已完结
-
Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy
10个月前
已完结